<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39339895</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1419</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091419</ELocationID><Abstract><AbstractText>Enterovirus-D68 (EV68) has emerged as a global health concern over the last decade with severe symptomatic infections resulting in long-lasting neurological deficits and death. Unfortunately, there are currently no FDA-approved antiviral drugs for EV68 or any other non-polio enterovirus. One particularly attractive class of potential drugs are small molecules inhibitors, which can target the conserved active site of EV68-3C protease. For other viral proteases, we have demonstrated that the emergence of drug resistance can be minimized by designing inhibitors that leverage the evolutionary constraints of substrate specificity. However, the structural characterization of EV68-3C protease bound to its substrates has been lacking. Here, we have determined the substrate specificity of EV68-3C protease through molecular modeling, molecular dynamics (MD) simulations, and co-crystal structures. Molecular models enabled us to successfully characterize the conserved hydrogen-bond networks between EV68-3C protease and the peptides corresponding to the viral cleavage sites. In addition, co-crystal structures we determined have revealed substrate-induced conformational changes of the protease which involved new interactions, primarily surrounding the S1 pocket. We calculated the substrate envelope, the three-dimensional consensus volume occupied by the substrates within the active site. With the elucidation of the EV68-3C protease substrate envelope, we evaluated how 3C protease inhibitors, AG7088 and SG-85, fit within the active site to predict potential resistance mutations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Azzolino</LastName><ForeName>Vincent N</ForeName><Initials>VN</Initials><Identifier Source="ORCID">0000-0003-3186-4760</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaqra</LastName><ForeName>Ala M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Akbar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurt Yilmaz</LastName><ForeName>Nese</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5036-676X</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiffer</LastName><ForeName>Celia A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-2270-6613</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM135919</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F30AI181515-01A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086042">3C Viral Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086042" MajorTopicYN="Y">3C Viral Proteases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="Y">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="Y">Viral Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="Y">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="Y">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020134" MajorTopicYN="Y">Catalytic Domain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV68</Keyword><Keyword MajorTopicYN="N">drug resistance</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">molecular modeling</Keyword><Keyword MajorTopicYN="N">protease</Keyword><Keyword MajorTopicYN="N">protein structure</Keyword><Keyword MajorTopicYN="N">substrate recognition</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339895</ArticleId><ArticleId IdType="pmc">PMC11437433</ArticleId><ArticleId IdType="doi">10.3390/v16091419</ArticleId><ArticleId IdType="pii">v16091419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pallansch M.A., Oberste M.S., Whitton J.L. In: Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and Newer Enteroviruses. 6th ed. Howley P.M., Knipe D.M., editors. Fields Virology Lippincott Williams &amp; Wilkins; Philadelphia, PA, USA: 2013.</Citation></Reference><Reference><Citation>Pons-Salort M., Parker E.P., Grassly N.C. The epidemiology of non-polio enteroviruses: Recent advances and outstanding questions. Curr. Opin. Infect. Dis. 2015;28:479–487. doi: 10.1097/QCO.0000000000000187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000187</ArticleId><ArticleId IdType="pmc">PMC6624138</ArticleId><ArticleId IdType="pubmed">26203854</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K., Abzug M.J., Dominguez S.R. 2014 outbreak of enterovirus D68 in North America. J. Med. Virol. 2016;88:739–745. doi: 10.1002/jmv.24410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24410</ArticleId><ArticleId IdType="pubmed">26489019</ArticleId></ArticleIdList></Reference><Reference><Citation>Waghmare A., Pergam S.A., Jerome K.R., Englund J.A., Boeckh M., Kuypers J. Clinical disease due to enterovirus D68 in adult hematologic malignancy patients and hematopoietic cell transplant recipients. Blood. 2015;125:1724–1729. doi: 10.1182/blood-2014-12-616516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-12-616516</ArticleId><ArticleId IdType="pmc">PMC4357580</ArticleId><ArticleId IdType="pubmed">25593338</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:368–381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W., Guo H., Chang J., Yu Y., Liu G., Zhang N., Willard S.H., Zheng S., Yu X.F. ICAM-5/Telencephalin Is a Functional Entry Receptor for Enterovirus D68. Cell Host Microbe. 2016;20:631–641. doi: 10.1016/j.chom.2016.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.09.013</ArticleId><ArticleId IdType="pubmed">27923705</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney J.A., Mirsky D.M., Messacar K., Dominguez S.R., Schreiner T., Stence N.V. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am. J. Neuroradiol. 2015;36:245–250. doi: 10.3174/ajnr.A4188.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A4188</ArticleId><ArticleId IdType="pmc">PMC7965662</ArticleId><ArticleId IdType="pubmed">25414005</ArticleId></ArticleIdList></Reference><Reference><Citation>Carballo C.M., Erro M.G., Sordelli N., Vazquez G., Mistchenko A.S., Cejas C., Rodriguez M., Cisterna D.M., Freire M.C., Contrini M.M., et al. Acute Flaccid Myelitis Associated with Enterovirus D68 in Children, Argentina, 2016. Emerg. Infect. Dis. 2019;25:573–576. doi: 10.3201/eid2503.170897.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2503.170897</ArticleId><ArticleId IdType="pmc">PMC6390768</ArticleId><ArticleId IdType="pubmed">30602120</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyda A., Stelzer-Braid S., Adam D., Chughtai A.A., MacIntyre C.R. The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68)—What is the evidence for causation? Eurosurveillance. 2018;23:17–00310. doi: 10.2807/1560-7917.ES.2018.23.3.17-00310.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2018.23.3.17-00310</ArticleId><ArticleId IdType="pmc">PMC5792700</ArticleId><ArticleId IdType="pubmed">29386095</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy O.C., Messacar K., Benson L., Bove R., Carpenter J.L., Crawford T., Dean J., DeBiasi R., Desai J., Elrick M.J., et al. Acute flaccid myelitis: Cause, diagnosis, and management. Lancet. 2021;397:334–346. doi: 10.1016/S0140-6736(20)32723-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32723-9</ArticleId><ArticleId IdType="pmc">PMC7909727</ArticleId><ArticleId IdType="pubmed">33357469</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K., Schreiner T.L., Van Haren K., Yang M., Glaser C.A., Tyler K.L., Dominguez S.R. Acute flaccid myelitis: A clinical review of US cases 2012–2015. Ann. Neurol. 2016;80:326–338. doi: 10.1002/ana.24730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24730</ArticleId><ArticleId IdType="pmc">PMC5098271</ArticleId><ArticleId IdType="pubmed">27422805</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove R., Rowles W., Carleton M., Olivera E., Sheehan M., Werdal H.P., Scott R., Axton L., Benson L. Unmet Needs in the Evaluation, Treatment, and Recovery for 167 Children Affected by Acute Flaccid Myelitis Reported by Parents through Social Media. Pediatr. Neurol. 2020;102:20–27. doi: 10.1016/j.pediatrneurol.2019.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2019.08.009</ArticleId><ArticleId IdType="pubmed">31630913</ArticleId></ArticleIdList></Reference><Reference><Citation>Melicosta M.E., Dean J., Hagen K., Oppenheimer K., Porter C., Rybczynski S., Salorio C., Sadowsky C. Acute flaccid myelitis: Rehabilitation challenges and outcomes in a pediatric cohort. J. Pediatr. Rehabil. Med. 2019;12:245–253. doi: 10.3233/PRM-180549.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/PRM-180549</ArticleId><ArticleId IdType="pubmed">31476175</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J.A., Messacar K., Yang M.L., Maloney J.A., Lindwall J., Carry T., Kenyon P., Sillau S.H., Oleszek J., Tyler K.L., et al. Outcomes of Colorado children with acute flaccid myelitis at 1 year. Neurology. 2017;89:129–137. doi: 10.1212/WNL.0000000000004081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004081</ArticleId><ArticleId IdType="pmc">PMC5501931</ArticleId><ArticleId IdType="pubmed">28615421</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D.M., Zhang Y., Scheuermann R.H. Epidemiology and Sequence-Based Evolutionary Analysis of Circulating Non-Polio Enteroviruses. Microorganisms. 2020;8:1856. doi: 10.3390/microorganisms8121856.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8121856</ArticleId><ArticleId IdType="pmc">PMC7759938</ArticleId><ArticleId IdType="pubmed">33255654</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliabadi N., Messacar K., Pastula D.M., Robinson C.C., Leshem E., Sejvar J.J., Nix W.A., Oberste M.S., Feikin D.R., Dominguez S.R. Enterovirus D68 Infection in Children with Acute Flaccid Myelitis, Colorado, USA, 2014. Emerg. Infect. Dis. 2016;22:1387–1394. doi: 10.3201/eid2208.151949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2208.151949</ArticleId><ArticleId IdType="pmc">PMC4982171</ArticleId><ArticleId IdType="pubmed">27434186</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., George S., Kusov Y., Perbandt M., Anemuller S., Mesters J.R., Norder H., Coutard B., Lacroix C., Leyssen P., et al. 3C protease of enterovirus 68: Structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J. Virol. 2013;87:4339–4351. doi: 10.1128/JVI.01123-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01123-12</ArticleId><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields B.N., Knipe D.M., Howley P.M. Fields Virology. 6th ed. Virology; Wolters Kluwer Health/Lippincott Williams &amp; Wilkins; Philadelphia, PA, USA: 2013.</Citation></Reference><Reference><Citation>De Palma A.M., Vliegen I., De Clercq E., Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 2008;28:823–884. doi: 10.1002/med.20125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20125</ArticleId><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cully M. A tale of two antiviral targets—And the COVID-19 drugs that bind them. Nat. Rev. Drug Discov. 2022;21:3–5. doi: 10.1038/d41573-021-00202-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00202-8</ArticleId><ArticleId IdType="pubmed">34857884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G., Qi J., Chen Z., Xu X., Gao F., Lin D., Qian W., Liu H., Jiang H., Yan J., et al. Enterovirus 71 and coxsackievirus A16 3C proteases: Binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 2011;85:10319–10331. doi: 10.1128/JVI.00787-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>King N.M., Prabu-Jeyabalan M., Nalivaika E.A., Schiffer C.A. Combating susceptibility to drug resistance: Lessons from HIV-1 protease. Chem. Biol. 2004;11:1333–1338. doi: 10.1016/j.chembiol.2004.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2004.08.010</ArticleId><ArticleId IdType="pubmed">15489160</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaqra A.M., Zvornicanin S.N., Huang Q.Y.J., Lockbaum G.J., Knapp M., Tandeske L., Bakan D.T., Flynn J., Bolon D.N.A., Moquin S., et al. Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat. Commun. 2022;13:3556. doi: 10.1038/s41467-022-31210-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31210-w</ArticleId><ArticleId IdType="pmc">PMC9211792</ArticleId><ArticleId IdType="pubmed">35729165</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano K.P., Ali A., Aydin C., Soumana D., Ozen A., Deveau L.M., Silver C., Cao H., Newton A., Petropoulos C.J., et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012;8:e1002832. doi: 10.1371/journal.ppat.1002832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002832</ArticleId><ArticleId IdType="pmc">PMC3406087</ArticleId><ArticleId IdType="pubmed">22910833</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano K.P., Ali A., Royer W.E., Schiffer C.A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. USA. 2010;107:20986–20991. doi: 10.1073/pnas.1006370107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006370107</ArticleId><ArticleId IdType="pmc">PMC3000259</ArticleId><ArticleId IdType="pubmed">21084633</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabu-Jeyabalan M., Nalivaika E., Schiffer C.A. Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes. Structure. 2002;10:369–381. doi: 10.1016/S0969-2126(02)00720-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-2126(02)00720-7</ArticleId><ArticleId IdType="pubmed">12005435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali A., Bandaranayake R.M., Cai Y., King N.M., Kolli M., Mittal S., Murzycki J.F., Nalam M.N.L., Nalivaika E.A., Ozen A., et al. Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses. 2010;2:2509–2535. doi: 10.3390/v2112509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v2112509</ArticleId><ArticleId IdType="pmc">PMC3185577</ArticleId><ArticleId IdType="pubmed">21994628</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalam M.N., Ali A., Reddy G.S., Cao H., Anjum S.G., Altman M.D., Yilmaz N.K., Tidor B., Rana T.M., Schiffer C.A. Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem. Biol. 2013;20:1116–1124. doi: 10.1016/j.chembiol.2013.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2013.07.014</ArticleId><ArticleId IdType="pmc">PMC3934494</ArticleId><ArticleId IdType="pubmed">24012370</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthew A.N., Leidner F., Lockbaum G.J., Henes M., Zephyr J., Hou S., Rao D.N., Timm J., Rusere L.N., Ragland D.A., et al. Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. Chem. Rev. 2021;121:3238–3270. doi: 10.1021/acs.chemrev.0c00648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.0c00648</ArticleId><ArticleId IdType="pmc">PMC8126998</ArticleId><ArticleId IdType="pubmed">33410674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozen A., Prachanronarong K., Matthew A.N., Soumana D.I., Schiffer C.A. Resistance outside the substrate envelope: Hepatitis C NS3/4A protease inhibitors. Crit. Rev. Biochem. Mol. Biol. 2019;54:11–26. doi: 10.1080/10409238.2019.1568962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10409238.2019.1568962</ArticleId><ArticleId IdType="pmc">PMC7717897</ArticleId><ArticleId IdType="pubmed">30821513</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthew A.N., Zephyr J., Nageswara Rao D., Henes M., Kamran W., Kosovrasti K., Hedger A.K., Lockbaum G.J., Timm J., Ali A., et al. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. mBio. 2020;11 doi: 10.1128/mBio.00172-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00172-20</ArticleId><ArticleId IdType="pmc">PMC7157764</ArticleId><ArticleId IdType="pubmed">32234812</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford S.L., Maldonado F., Brothers M.A., Weady P.T., Zalman L.S., Meador J.W., 3rd, Matthews D.A., Patick A.K. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 2005;49:619–626. doi: 10.1128/AAC.49.2.619-626.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.2.619-626.2005</ArticleId><ArticleId IdType="pmc">PMC547258</ArticleId><ArticleId IdType="pubmed">15673742</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews D.A., Dragovich P.S., Webber S.E., Fuhrman S.A., Patick A.K., Zalman L.S., Hendrickson T.F., Love R.A., Prins T.J., Marakovits J.T., et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. USA. 1999;96:11000–11007. doi: 10.1073/pnas.96.20.11000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11000</ArticleId><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Binford S.L., Brothers M.A., Jackson R.L., Ford C.E., Diem M.D., Maldonado F., Dragovich P.S., Zhou R., Prins T.J., et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 1999;43:2444–2450. doi: 10.1128/AAC.43.10.2444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.10.2444</ArticleId><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Brothers M.A., Maldonado F., Binford S., Maldonado O., Fuhrman S., Petersen A., Smith G.J., 3rd, Zalman L.S., Burns-Naas L.A., et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 2005;49:2267–2275. doi: 10.1128/AAC.49.6.2267-2275.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.6.2267-2275.2005</ArticleId><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Prins T.J., Zhou R., Fuhrman S.A., Patick A.K., Matthews D.A., Ford C.E., Meador J.W., 3rd, Ferre R.A., Worland S.T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J. Med. Chem. 1999;42:1203–1212. doi: 10.1021/jm980537b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm980537b</ArticleId><ArticleId IdType="pubmed">10197964</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Prins T.J., Zhou R., Johnson T.O., Hua Y., Luu H.T., Sakata S.K., Brown E.L., Maldonado F.C., Tuntland T., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J. Med. Chem. 2003;46:4572–4585. doi: 10.1021/jm030166l.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm030166l</ArticleId><ArticleId IdType="pubmed">14521419</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Prins T.J., Zhou R., Webber S.E., Marakovits J.T., Fuhrman S.A., Patick A.K., Matthews D.A., Lee C.A., Ford C.E., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 1999;42:1213–1224. doi: 10.1021/jm9805384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9805384</ArticleId><ArticleId IdType="pubmed">10197965</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Webber S.E., Babine R.E., Fuhrman S.A., Patick A.K., Matthews D.A., Lee C.A., Reich S.H., Prins T.J., Marakovits J.T., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J. Med. Chem. 1998;41:2806–2818. doi: 10.1021/jm980068d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm980068d</ArticleId><ArticleId IdType="pubmed">9667970</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Webber S.E., Babine R.E., Fuhrman S.A., Patick A.K., Matthews D.A., Reich S.H., Marakovits J.T., Prins T.J., Zhou R., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J. Med. Chem. 1998;41:2819–2834. doi: 10.1021/jm9800696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9800696</ArticleId><ArticleId IdType="pubmed">9667971</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Zhou R., Skalitzky D.J., Fuhrman S.A., Patick A.K., Ford C.E., Meador J.W., 3rd, Worland S.T. Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides. Bioorg. Med. Chem. 1999;7:589–598. doi: 10.1016/S0968-0896(99)00005-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0968-0896(99)00005-X</ArticleId><ArticleId IdType="pubmed">10353638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockbaum G.J., Henes M., Lee J.M., Timm J., Nalivaika E.A., Thompson P.R., Kurt Yilmaz N., Schiffer C.A. Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode. Biochemistry. 2021;60:2925–2931. doi: 10.1021/acs.biochem.1c00414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.1c00414</ArticleId><ArticleId IdType="pmc">PMC8457326</ArticleId><ArticleId IdType="pubmed">34506130</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalam M.N., Ali A., Altman M.D., Reddy G.S., Chellappan S., Kairys V., Ozen A., Cao H., Gilson M.K., Tidor B., et al. Evaluating the substrate-envelope hypothesis: Structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J. Virol. 2010;84:5368–5378. doi: 10.1128/JVI.02531-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02531-09</ArticleId><ArticleId IdType="pmc">PMC2863851</ArticleId><ArticleId IdType="pubmed">20237088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockbaum G.J., Leidner F., Rusere L.N., Henes M., Kosovrasti K., Nachum G.S., Nalivaika E.A., Ali A., Yilmaz N.K., Schiffer C.A. Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease. ACS Infect. Dis. 2019;5:316–325. doi: 10.1021/acsinfecdis.8b00336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.8b00336</ArticleId><ArticleId IdType="pmc">PMC6941150</ArticleId><ArticleId IdType="pubmed">30543749</ArticleId></ArticleIdList></Reference><Reference><Citation>Henes M., Lockbaum G.J., Kosovrasti K., Leidner F., Nachum G.S., Nalivaika E.A., Lee S.K., Spielvogel E., Zhou S., Swanstrom R., et al. Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance. ACS Chem. Biol. 2019;14:2441–2452. doi: 10.1021/acschembio.9b00370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.9b00370</ArticleId><ArticleId IdType="pmc">PMC6941144</ArticleId><ArticleId IdType="pubmed">31361460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockbaum G.J., Henes M., Talledge N., Rusere L.N., Kosovrasti K., Nalivaika E.A., Somasundaran M., Ali A., Mansky L.M., Kurt Yilmaz N., et al. Inhibiting HTLV-1 Protease: A Viable Antiviral Target. ACS Chem. Biol. 2021;16:529–538. doi: 10.1021/acschembio.0c00975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.0c00975</ArticleId><ArticleId IdType="pmc">PMC8126997</ArticleId><ArticleId IdType="pubmed">33619959</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford S.L., Weady P.T., Maldonado F., Brothers M.A., Matthews D.A., Patick A.K. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 2007;51:4366–4373. doi: 10.1128/AAC.00905-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00905-07</ArticleId><ArticleId IdType="pmc">PMC2167992</ArticleId><ArticleId IdType="pubmed">17908951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozen A., Haliloglu T., Schiffer C.A. Dynamics of preferential substrate recognition in HIV-1 protease: Redefining the substrate envelope. J. Mol. Biol. 2011;410:726–744. doi: 10.1016/j.jmb.2011.03.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.03.053</ArticleId><ArticleId IdType="pmc">PMC3139114</ArticleId><ArticleId IdType="pubmed">21762811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozen A., Sherman W., Schiffer C.A. Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design. J. Chem. Theory Comput. 2013;9:5693–5705. doi: 10.1021/ct400603p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct400603p</ArticleId><ArticleId IdType="pmc">PMC3935243</ArticleId><ArticleId IdType="pubmed">24587770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W. Xds. Pt 2Acta Crystallogr. D Biol. Crystallogr. 2010;66:125–132. doi: 10.1107/S0907444909047337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909047337</ArticleId><ArticleId IdType="pmc">PMC2815665</ArticleId><ArticleId IdType="pubmed">20124692</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007;40:658–674. doi: 10.1107/S0021889807021206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0021889807021206</ArticleId><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Cowtan K. Coot: Model-building tools for molecular graphics. Pt 1Acta Crystallogr. D Biol. Crystallogr. 2004;60:2126–2132. doi: 10.1107/S0907444904019158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444904019158</ArticleId><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Pt 4Acta Crystallogr. D Biol. Crystallogr. 2010;66:486–501. doi: 10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Pt 2Acta Crystallogr. D Biol. Crystallogr. 2010;66:213–221. doi: 10.1107/S0907444909052925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909052925</ArticleId><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunger A.T. Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature. 1992;355:472–475. doi: 10.1038/355472a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/355472a0</ArticleId><ArticleId IdType="pubmed">18481394</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrödinger . Schrödinger Release 2019–2. Schrödinger LLC; New York, NY, USA: 2019.</Citation></Reference><Reference><Citation>Leidner F., Kurt Yilmaz N., Paulsen J., Muller Y.A., Schiffer C.A. Hydration Structure and Dynamics of Inhibitor-Bound HIV-1 Protease. J. Chem. Theory Comput. 2018;14:2784–2796. doi: 10.1021/acs.jctc.8b00097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.8b00097</ArticleId><ArticleId IdType="pmc">PMC6219750</ArticleId><ArticleId IdType="pubmed">29570286</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson M.P., Friesner R.A., Xiang Z., Honig B. On the role of the crystal environment in determining protein side-chain conformations. J. Mol. Biol. 2002;320:597–608. doi: 10.1016/S0022-2836(02)00470-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(02)00470-9</ArticleId><ArticleId IdType="pubmed">12096912</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson M.H., Sondergaard C.R., Rostkowski M., Jensen J.H. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. J. Chem. Theory Comput. 2011;7:525–537. doi: 10.1021/ct100578z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct100578z</ArticleId><ArticleId IdType="pubmed">26596171</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder E., Damm W., Maple J., Wu C., Reboul M., Xiang J.Y., Wang L., Lupyan D., Dahlgren M.K., Knight J.L., et al. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. J. Chem. Theory Comput. 2016;12:281–296. doi: 10.1021/acs.jctc.5b00864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.5b00864</ArticleId><ArticleId IdType="pubmed">26584231</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidner F., Kurt Yilmaz N., Schiffer C.A. Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning. J. Chem. Theory Comput. 2021;17:2054–2064. doi: 10.1021/acs.jctc.0c01244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.0c01244</ArticleId><ArticleId IdType="pmc">PMC8164521</ArticleId><ArticleId IdType="pubmed">33783217</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali A., Aydin C., Gildemeister R., Romano K.P., Cao H., Ozen A., Soumana D., Newton A., Petropoulos C.J., Huang W., et al. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem. Biol. 2013;8:1469–1478. doi: 10.1021/cb400100g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cb400100g</ArticleId><ArticleId IdType="pmc">PMC3884027</ArticleId><ArticleId IdType="pubmed">23594083</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>